Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Tax Provisions (2023)

Foghorn Therapeutics has reported Tax Provisions over the past 1 years, most recently at $2.0 million for Q4 2023.

  • Quarterly results put Tax Provisions at $2.0 million for Q4 2023, changed N/A from a year ago — trailing twelve months through Sep 2024 was $2.0 million (down 11.34% YoY), and the annual figure for FY2023 was $4.2 million, changed.
  • Tax Provisions for Q4 2023 was $2.0 million at Foghorn Therapeutics, up from $738000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for FHTX hit a ceiling of $2.0 million in Q4 2023 and a floor of $560000.0 in Q1 2023.